Literature DB >> 26403783

Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers.

Louisa Mezache1, Bernard Paniccia1, Angelique Nyinawabera1, Gerard J Nuovo1,2.   

Abstract

Programmed death ligand 1 (PD L1) expression can reduce the immune response in both infectious diseases and cancers. We thus examined PD L1 expression in cervical intraepithelial neoplasias (CINs) and cancers since they each reflect infection by human papillomavirus (HPV). PD L1 protein was not evident by immunohistochemistry in histologically normal cervical epithelia (0/55) even when adjacent to CIN or cancer. PD L1 expression was much increased in CINs (20/21=95%) and cervical squamous cell cancer (56/70=80%) and localized to the dysplastic/neoplastic squamous cells and mononuclear cells, respectively. There was also a significant increase (each P<0.001) in PD L1 detection in mononuclear cells when comparing cervical squamous cell cancers to endometrial (22/115=19%) and ovarian adenocarcinomas (5/40=13%). Co-expression analyses showed that the primary inflammatory cell that contained PD L1 was the CD8+ lymphocyte that strongly concentrated around the dysplastic CIN cells and nests of invasive squamous cancer cells. These data show that PD L1 is a solid biomarker of productive HPV infection of the cervix and that it is significantly upregulated in both the carcinoma and surrounding inflammatory cells in cervical cancer when compared with other gynecologic malignancies. This suggests that anti-PD L1 therapy may have a role in the treatment of cervical cancer.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26403783     DOI: 10.1038/modpathol.2015.108

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  21 in total

Review 1.  The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature.

Authors:  Evangelos Paraskevaidis; Marc Arbyn; Alexandros Sotiriadis; Emmanuel Diakomanolis; Pierre Martin-Hirsch; George Koliopoulos; George Makrydimas; Jovan Tofoski; Dimitrios H Roukos
Journal:  Cancer Treat Rev       Date:  2004-04       Impact factor: 12.111

2.  Accumulation of RNA homologous to human papillomavirus type 16 open reading frames in genital precancers.

Authors:  C P Crum; G Nuovo; D Friedman; S J Silverstein
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

3.  Human papillomavirus 16-associated cervical intraepithelial neoplasia in humans excludes CD8 T cells from dysplastic epithelium.

Authors:  Cornelia L Trimble; Rachael A Clark; Christopher Thoburn; Nicole C Hanson; Jodie Tassello; Denise Frosina; Ferdynand Kos; Jessica Teague; Ying Jiang; Nicole C Barat; Achim A Jungbluth
Journal:  J Immunol       Date:  2010-10-29       Impact factor: 5.422

4.  Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18.

Authors:  Luisa L Villa; Kevin A Ault; Anna R Giuliano; Ronaldo L R Costa; Carlos A Petta; Rosires P Andrade; Darron R Brown; Alex Ferenczy; Diane M Harper; Laura A Koutsky; Robert J Kurman; Matti Lehtinen; Christian Malm; Sven-Eric Olsson; Brigitte M Ronnett; Finn Egil Skjeldestad; Margareta Steinwall; Mark H Stoler; Cosette M Wheeler; Frank J Taddeo; Jimmy Yu; Lisa Lupinacci; Radha Railkar; Rocio Marchese; Mark T Esser; Janine Bryan; Kathrin U Jansen; Heather L Sings; Gretchen M Tamms; Alfred J Saah; Eliav Barr
Journal:  Vaccine       Date:  2006-05-15       Impact factor: 3.641

5.  Histological 'progression' from low (LSIL) to high (HSIL) squamous intraepithelial lesion is an uncommon event and an indication for quality assurance review.

Authors:  Eleanor Y Chen; Ann Tran; Caroline J Raho; Chandler M Birch; Christopher P Crum; Michelle S Hirsch
Journal:  Mod Pathol       Date:  2010-05-14       Impact factor: 7.842

6.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

7.  Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples.

Authors:  Gerard J Nuovo; Michela Garofalo; Nicola Valeri; Vicki Roulstone; Stefano Volinia; David E Cohn; Mitch Phelps; Kevin J Harrington; Richard Vile; Alan Melcher; Evanthia Galanis; Sarah Sehl; Rob Adair; Karen Scott; Ailsa Rose; Giles Toogood; Matthew C Coffey
Journal:  Mod Pathol       Date:  2012-06-15       Impact factor: 7.842

8.  Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.

Authors:  Eva Herweijer; Amy Leval; Alexander Ploner; Sandra Eloranta; Julia Fridman Simard; Joakim Dillner; Eva Netterlid; Pär Sparén; Lisen Arnheim-Dahlström
Journal:  JAMA       Date:  2014-02-12       Impact factor: 56.272

Review 9.  The virology of cervical neoplasia: an HPV-associated malignancy.

Authors:  Mark H Stoler
Journal:  Cancer J       Date:  2003 Sep-Oct       Impact factor: 3.360

10.  PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Authors:  Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

View more
  83 in total

1.  Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy.

Authors:  Matthew P Morrow; Kimberly A Kraynyak; Cornelia L Trimble; Mark L Bagarazzi; Albert J Sylvester; Michael Dallas; Dawson Knoblock; Jean D Boyer; Jian Yan; Russell Vang; Amir S Khan; Laurent Humeau; Niranjan Y Sardesai; J Joseph Kim; Stanley Plotkin; David B Weiner
Journal:  Clin Cancer Res       Date:  2017-10-30       Impact factor: 12.531

2.  PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer.

Authors:  Ozlen Saglam; Jose Conejo-Garcia
Journal:  Integr Cancer Sci Ther       Date:  2018-04-14

Review 3.  Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine.

Authors:  Dmitriy Zamarin; Amir A Jazaeri
Journal:  Gynecol Oncol       Date:  2016-04       Impact factor: 5.482

4.  CD274 (PD-L1), CDKN2A (p16), TP53, and EGFR immunohistochemical profile in primary, recurrent and metastatic vulvar cancer.

Authors:  Sofia Lérias; Susana Esteves; Fernanda Silva; Mário Cunha; Daniela Cochicho; Luís Martins; Ana Félix
Journal:  Mod Pathol       Date:  2019-12-16       Impact factor: 7.842

5.  Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer.

Authors:  Emeka K Enwere; Elizabeth N Kornaga; Michelle Dean; Theodora A Koulis; Tien Phan; Maria Kalantarian; Martin Köbel; Prafull Ghatage; Anthony M Magliocco; Susan P Lees-Miller; Corinne M Doll
Journal:  Mod Pathol       Date:  2017-01-06       Impact factor: 7.842

6.  Moving forward with human papillomavirus immunotherapies.

Authors:  Nicolas Çuburu; John T Schiller
Journal:  Hum Vaccin Immunother       Date:  2016-07-07       Impact factor: 3.452

7.  Response to Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer: The Role of Immune-related Factors.

Authors:  Innocenza Palaia; Federica Tomao; Anna DI Pinto; Angelina Pernazza; Giusi Santangelo; Nicoletta D'Alessandris; Lucia Manganaro; Antonio Arno; Violante DI Donato; Giorgia Perniola; Carlo Della Rocca; Pierluigi Benedetti Panici
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

Review 8.  Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis.

Authors:  Nitin Chakravarti; Victor G Prieto
Journal:  Transl Lung Cancer Res       Date:  2015-12

9.  Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8+ T cell responses against HPV16 oncoproteins.

Authors:  Nicolas Çuburu; Selina Khan; Cynthia D Thompson; Rina Kim; Jort Vellinga; Roland Zahn; Douglas R Lowy; Gert Scheper; John T Schiller
Journal:  Int J Cancer       Date:  2017-12-01       Impact factor: 7.396

10.  Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches.

Authors:  A M Udager; T-Y Liu; S L Skala; M J Magers; A S McDaniel; D E Spratt; F Y Feng; J Siddiqui; X Cao; K L Fields; T M Morgan; G S Palapattu; A Z Weizer; A M Chinnaiyan; A Alva; J S Montgomery; S A Tomlins; H Jiang; R Mehra
Journal:  Ann Oncol       Date:  2016-05-23       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.